AstraZeneca is buying Fusion Pharmaceuticals, a Canadian company specializing in radioconjugation cancer treatments, for $2.4 billion.
Petru Nicolaescu
Health
Unsplash.com
Always see our news on Google
The acquisition of Fusion Pharmaceuticals by AstraZeneca brings innovative new treatments to the company's portfolio. Radioconjugates developed by Fusion are an alternative to chemotherapy and radiotherapy, minimizing damage to healthy cells. The most advanced treatment, FPI-2265, is for patients with metastatic prostate cancer.
Latest News
14:39
Israel Katz warns that operations against Iran could continue and accuses Tehran of trying to obtain a nuclear weapon
14:10
Russian attacks have left more than 850,000 consumers in the Dnipropetrovsk and Kharkiv regions without electricity
13:52
The Polish prosecutor's office opens a "terrorism" investigation after the armed attack in Kraków
13:35
Romania’s government debt increased to 61.1% of GDP in August 2026, compared with 59.8% in the previous month
13:23
Alexandru Nazare is participating on Monday in the ECOFIN and Eurogroup meetings in Brussels
See more news
NEWS ON THE SAME TOPICS
IT&C knowledge
Novo collaborates with Anthropic to use artificial intelligence in the research and development of new medicines
International
An experimental cancer vaccine, developed by Moderna and Merck, has shown promising results in patients with melanoma.
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
